Chris Schott
Stock Analyst at JP Morgan
(4.10)
# 527
Out of 5,124 analysts
151
Total ratings
66.35%
Success rate
7.94%
Average return
Main Sectors:
Stocks Rated by Chris Schott
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TEVA Teva Pharmaceutical Industries | Maintains: Overweight | $28 → $35 | $31.21 | +12.14% | 20 | Dec 16, 2025 | |
| PRGO Perrigo Company | Maintains: Neutral | $20 → $18 | $13.92 | +29.31% | 14 | Dec 15, 2025 | |
| LLY Eli Lilly and Company | Maintains: Overweight | $1,050 → $1,150 | $1,074.68 | +7.01% | 23 | Nov 18, 2025 | |
| OGN Organon & Co. | Maintains: Underweight | $14 → $12 | $7.17 | +67.36% | 3 | Nov 11, 2025 | |
| ZTS Zoetis | Maintains: Overweight | $230 → $200 | $125.82 | +58.96% | 3 | Nov 5, 2025 | |
| IDXX IDEXX Laboratories | Maintains: Overweight | $675 → $775 | $676.53 | +14.56% | 9 | Nov 4, 2025 | |
| ABBV AbbVie | Maintains: Overweight | $250 → $260 | $228.49 | +13.79% | 4 | Nov 3, 2025 | |
| GILD Gilead Sciences | Maintains: Overweight | $145 → $150 | $122.74 | +22.21% | 8 | Oct 31, 2025 | |
| ELAN Elanco Animal Health | Upgrades: Overweight | $18 → $24 | $22.63 | +6.05% | 4 | Oct 7, 2025 | |
| AMRX Amneal Pharmaceuticals | Maintains: Overweight | $12 → $14 | $12.60 | +11.11% | 3 | Sep 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $950 → $800 | $771.87 | +3.64% | 8 | Jun 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $185 → $175 | $175.99 | -0.56% | 4 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $42 | $38.64 | +8.70% | 4 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $270 | $327.31 | -17.51% | 1 | Oct 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $36 → $34 | $24.90 | +36.55% | 10 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $120 → $125 | $105.26 | +18.75% | 7 | Feb 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $14 | $12.45 | +12.45% | 2 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $11 | $1.43 | +670.85% | 4 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $6.95 | - | 4 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $74 → $78 | $53.94 | +44.61% | 7 | Oct 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $700 → $950 | $0.56 | +170,794.05% | 4 | May 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.63 | - | 2 | May 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $45 → $50 | $25.88 | +93.20% | 3 | Nov 2, 2018 |
Teva Pharmaceutical Industries
Dec 16, 2025
Maintains: Overweight
Price Target: $28 → $35
Current: $31.21
Upside: +12.14%
Perrigo Company
Dec 15, 2025
Maintains: Neutral
Price Target: $20 → $18
Current: $13.92
Upside: +29.31%
Eli Lilly and Company
Nov 18, 2025
Maintains: Overweight
Price Target: $1,050 → $1,150
Current: $1,074.68
Upside: +7.01%
Organon & Co.
Nov 11, 2025
Maintains: Underweight
Price Target: $14 → $12
Current: $7.17
Upside: +67.36%
Zoetis
Nov 5, 2025
Maintains: Overweight
Price Target: $230 → $200
Current: $125.82
Upside: +58.96%
IDEXX Laboratories
Nov 4, 2025
Maintains: Overweight
Price Target: $675 → $775
Current: $676.53
Upside: +14.56%
AbbVie
Nov 3, 2025
Maintains: Overweight
Price Target: $250 → $260
Current: $228.49
Upside: +13.79%
Gilead Sciences
Oct 31, 2025
Maintains: Overweight
Price Target: $145 → $150
Current: $122.74
Upside: +22.21%
Elanco Animal Health
Oct 7, 2025
Upgrades: Overweight
Price Target: $18 → $24
Current: $22.63
Upside: +6.05%
Amneal Pharmaceuticals
Sep 16, 2025
Maintains: Overweight
Price Target: $12 → $14
Current: $12.60
Upside: +11.11%
Jun 9, 2025
Maintains: Overweight
Price Target: $950 → $800
Current: $771.87
Upside: +3.64%
May 5, 2025
Maintains: Neutral
Price Target: $185 → $175
Current: $175.99
Upside: -0.56%
Feb 20, 2024
Maintains: Overweight
Price Target: $45 → $42
Current: $38.64
Upside: +8.70%
Oct 20, 2023
Reinstates: Neutral
Price Target: $270
Current: $327.31
Upside: -17.51%
Oct 16, 2023
Maintains: Neutral
Price Target: $36 → $34
Current: $24.90
Upside: +36.55%
Feb 23, 2023
Maintains: Overweight
Price Target: $120 → $125
Current: $105.26
Upside: +18.75%
Nov 15, 2022
Maintains: Neutral
Price Target: $13 → $14
Current: $12.45
Upside: +12.45%
Nov 14, 2022
Maintains: Neutral
Price Target: $13 → $11
Current: $1.43
Upside: +670.85%
Jul 29, 2022
Downgrades: Neutral
Price Target: n/a
Current: $6.95
Upside: -
Oct 16, 2020
Maintains: Overweight
Price Target: $74 → $78
Current: $53.94
Upside: +44.61%
May 27, 2020
Maintains: Overweight
Price Target: $700 → $950
Current: $0.56
Upside: +170,794.05%
May 19, 2020
Downgrades: Neutral
Price Target: n/a
Current: $1.63
Upside: -
Nov 2, 2018
Maintains: Neutral
Price Target: $45 → $50
Current: $25.88
Upside: +93.20%